Skip to main content
OpenTrials
Completed

NCT Number: NCT03923114

Imaging Pituitary ActiVation by Exendin

The main goal is the comparison of pituitary uptake of Ga-68-NODAGA-exendin-4 in patients with and without adequate response (based on HbA1c or weight loss) to GLP-1R agonist treatment.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Radboud university medical center

Nijmegen, Gelderland, 6525 GA, Netherlands

About this study

The prevalence of type 2 diabetes (T2D) is increasing and a better understanding of the mechanisms of T2D becomes increasingly important. The glucagon-like peptide 1 receptor agonists (GLP-1RA), such as exendin, can be used as potent antidiabetic drugs for treatment of T2D. Not all patients with T2D respond to treatment with GLP-1RA and some even respond with contradictory effects, but the underlying mechanism for this observation remains unclear. Interestingly, uptake of an exendin-based radiotracer was observed in the pituitary gland in diabetes patients. In this study, the effect of GLP-1RA on the HPA axis will be further studied for an improved understanding of the mechanisms and contradictory treatment responses.

Patient data will be obtained and will consist of metabolic characterization (laboratory parameters and oral glucose tolerance test), an ACTH assay and determination of cortisol excretion. In addition, Ga-68-NODAGA-exendin-4 PET/CT imaging will be performed in 10 patients with treatment response (decrease in HbA1c or weight loss) and 10 patients without response after GLP-1RA therapy. In 5 patients with high radiotracer uptake, an additional brain MRI scan will be performed for improved anatomical referencing.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with treatment response:

  • Age ≥18 years
  • Subject is diagnosed with type 2 diabetes
  • Subject showed response to GLP-1RA treatment
  • Ability to sign informed consent

Patients without treatment response:

  • Age ≥18 years
  • Subject is diagnosed with type 2 diabetes
  • Subject showed no response to GLP-1RA treatment
  • Ability to sign informed consent

Exclusion criteria

  • Liver disease
  • Renal disease
  • Pregnancy or the wish to become pregnant within 6 months after the study
  • Breastfeeding
  • Age <18 years
  • Pituitary disorder
  • Inability to sign informed consent
  • Exclusion criteria for MR:
  • Fragments, clips or devices in brain, eyes, spinal canal
  • Implantable defibrillator or pacemaker (wires)
  • Mandibular magnetic implants
  • Neurostimulator, bladder stimulator, non-removable insulin pump
  • Metal tissue-expander in chest
  • Cochlear implant
  • Ossicular replacement prosthesis

Treatment and study plan

Ga-68-NODAGA-exendin-4 PET/CT

Radiation

PET/CT imaging after injection with Ga-68-NODAGA-exendin-4

Primary outcomes

  1. Pituitary uptake of Ga-68-NODAGA-exendin

    Time frame: 1.5 year

    Comparison of the pituitary uptake (Bq) of Ga-68-NODAGA-exendin-4 obtained by quantitative analysis

Secondary outcomes

  1. Metabolic status (OGTT)

    Time frame: 1.5 year

    Assessment of the metabolic status by performing an OGTT (mmol/l)

  2. Metabolic status (ACTH)

    Time frame: 1.5 year

    Assessment of the metabolic status by performing an ACTH assay (mol/l)

Sponsors and collaborators

Lead sponsor

Radboud University Medical Center

Other

Registry information

Official study title

iPAVE - Imaging Pituitary ActiVation by Exendin

Acronym: iPAVE

Important dates

Study start
2019
Primary completion
2024
Study completion
2024
First posted
Apr 22, 2019
Registry last updated
May 22, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.